CONMED (CNMD) Aktienübersicht
CONMED Corporation, ein Medizintechnikunternehmen, entwickelt, produziert und vertreibt Geräte und Ausrüstungen für chirurgische Eingriffe. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 1/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
CNMD Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CONMED Corporation Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$51.07 |
| 52-Wochen-Hoch | US$56.64 |
| 52-Wochen-Tief | US$31.44 |
| Beta | 0.90 |
| 1 Monat Veränderung | 19.66% |
| 3 Monate Veränderung | 37.17% |
| 1 Jahr Veränderung | -8.49% |
| 3 Jahre Veränderung | -52.70% |
| 5 Jahre Veränderung | -62.02% |
| Veränderung seit IPO | 2,453.50% |
Aktuelle Nachrichten und Updates
Seeking Alpha • Aug 18
CONMED Corporation: Organic Growth Is Masked By Divestitures
Summary Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy. Read the full article on Seeking Alpha
Narrative-Update • Aug 14
CNMD: Gastro Exit And Potential Sale Interest Will Shape Future Upside
Analysts have raised the implied fair value for CONMED to $45.50 from $39.60, reflecting higher Street price targets clustered around $45 after recent Q2 outperformance, one-time tariff benefits, and renewed interest from potential financial and strategic buyers. Analyst Commentary Recent research on Conmed shows a split between investors focused on potential sale value and those focused on execution risks and relative appeal within medtech.
Narrative-Update • Jul 31
CNMD: Potential Sale And Surgical Reset Will Shape Next Chapter
Analysts have lifted their fair value estimate for Conmed to $49 from $40. This reflects updated assumptions on growth, profitability, and future P/E that are broadly consistent with recent price target increases to $45 and commentary around potential sale scenarios in the $46 to $53 range.
Narrative-Update • Jul 16
CNMD: Sale Hopes Will Face Debt And Execution Headwinds Through 2026
CONMED's analyst price target has been modestly reset closer to $36, as analysts weigh slightly higher modeled revenue growth and margins against updated assumptions around valuation multiples and the potential for private equity interest highlighted in recent research. Analyst Commentary Recent research on CONMED reflects a mixed backdrop, with several firms taking a more cautious stance even as takeover speculation and private equity interest attract attention.Recent updates
Seeking Alpha • Aug 18
CONMED Corporation: Organic Growth Is Masked By Divestitures
Summary Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy. Read the full article on Seeking AlphaNarrative-Update • Aug 14
CNMD: Gastro Exit And Potential Sale Interest Will Shape Future Upside
Analysts have raised the implied fair value for CONMED to $45.50 from $39.60, reflecting higher Street price targets clustered around $45 after recent Q2 outperformance, one-time tariff benefits, and renewed interest from potential financial and strategic buyers. Analyst Commentary Recent research on Conmed shows a split between investors focused on potential sale value and those focused on execution risks and relative appeal within medtech.Narrative-Update • Jul 31
CNMD: Potential Sale And Surgical Reset Will Shape Next Chapter
Analysts have lifted their fair value estimate for Conmed to $49 from $40. This reflects updated assumptions on growth, profitability, and future P/E that are broadly consistent with recent price target increases to $45 and commentary around potential sale scenarios in the $46 to $53 range.Narrative-Update • Jul 16
CNMD: Sale Hopes Will Face Debt And Execution Headwinds Through 2026
CONMED's analyst price target has been modestly reset closer to $36, as analysts weigh slightly higher modeled revenue growth and margins against updated assumptions around valuation multiples and the potential for private equity interest highlighted in recent research. Analyst Commentary Recent research on CONMED reflects a mixed backdrop, with several firms taking a more cautious stance even as takeover speculation and private equity interest attract attention.Narrative-Update • Jul 02
CNMD: Gastro Exit And Buybacks Will Support Future Profit Margin Upside
Analysts have lowered their price expectations for CONMED, with the updated target moving to $40. This reflects a shift toward lower assumed revenue growth and P/E multiples, even as projected profit margins edge higher in their models.Narrative-Update • Jun 18
CNMD: Refocused Surgical Portfolio And Buybacks Will Test Medtech Reset
Analysts have reset their price target on CONMED to $40, down from $52, citing a broader reassessment of medtech valuations in a year with fewer product cycles, along with rising concerns around healthcare utilization and inflation. Analyst Commentary Recent commentary on CONMED highlights that the lower US$40 price target sits within a broader reset for medtech valuations, rather than being tied to a single company specific issue.Narrative-Update • Jun 04
CNMD: Reset Medtech Expectations Will Set Stage For 2026 Guidance Reassessment
Analysts have trimmed their price targets on CONMED, with figures such as BofA cutting its target to $40 and another firm moving to $39. This reflects a reset in medtech valuations, as well as concerns around product execution and limited near term catalysts.Narrative-Update • May 20
CNMD: Execution And Margin Stability Will Be Tested In Medtech Reset
Analysts have reduced CONMED's fair value estimate and price target to $40 from $52. They cite a reset in medtech valuations, concerns around product cycles and utilization, and a lower assumed future P/E multiple, while keeping revenue growth and profit margin assumptions broadly steady.Narrative-Update • May 01
CNMD: Execution Repairs And Margin Stability Will Support Future Upside
Narrative Update Overview Analysts have trimmed their average price targets on CONMED by $3, alongside neutral ratings and concerns around product execution and a lack of near term catalysts, even as updated assumptions reflect steady revenue growth, profit margins around 10.8% and a slightly lower future P/E multiple. Analyst Commentary Recent research on CONMED has centered on valuation reset, execution around key products, and the search for clear catalysts, with JPMorgan trimming its price target by $3 and other firms shifting to more neutral stances.Narrative-Update • Apr 17
CNMD: Execution Questions And Limited Catalysts Will Shape Balanced Risk Profile
Analysts have reset their price target on CONMED to $39, trimming it by $16 from the prior $55. They cite concerns around AirSeal competition, recent execution issues, and a lack of clear near term catalysts for a turnaround in sentiment.Narrative-Update • Apr 02
CNMD: Execution Rebound And Margin Focus Will Support Future Upside
The analyst price target for CONMED has been reduced by $3 to $52, as analysts factor in a slightly higher discount rate and a lower future P/E multiple while still modeling modestly higher revenue growth and profit margins, and acknowledging recent downgrades that highlight concerns around execution and a lack of near term catalysts. Analyst Commentary Recent research on CONMED reflects a mixed setup, with some analysts focused on execution risks and a lack of clear near term catalysts, while others maintain a more balanced stance that supports a mid range valuation and steady expectations.Narrative-Update • Mar 18
CNMD: Execution Concerns And Leadership Transition Will Shape Balanced Risk Profile
Narrative Update: CONMED Price Target Shift The analyst price target for CONMED has been revised from $42 to $39, with analysts pointing to execution missteps, weaker sentiment around the AirSeal product, and a lack of clear near term catalysts as key reasons for the adjustment. Analyst Commentary Recent Street research on CONMED has tilted more cautious, with several bearish analysts highlighting execution risk, questions around AirSeal, and a limited near term catalyst path to re-rate the shares.Narrative-Update • Mar 04
CNMD: Portfolio Refocus And Leadership Change Will Shape Balanced Risk Profile
Narrative Update on CONMED Analysts kept their $42 price target for CONMED unchanged. They cited slightly higher assumed revenue growth and profit margins along with a modestly lower discount rate and future P/E, which together support a steady valuation view despite ongoing sector volatility highlighted in recent research.Narrative-Update • Feb 17
CNMD: Portfolio Refocus And Higher Future P/E Will Support Returns
Analysts maintained their fair value estimate for CONMED at $55.00 and refreshed their price target framework to incorporate more conservative assumptions for revenue growth and profit margins, while also reflecting a higher future P/E multiple. Analyst Commentary Bullish analysts appear comfortable holding their US$55.00 fair value estimate for CONMED while updating models to reflect more conservative assumptions for revenue growth and margins.Narrative-Update • Feb 03
CNMD: Future Portfolio Shift And Capital Moves Signal Balanced Risk Profile
Analysts have reduced their price target on CONMED to US$42 from US$55, citing a higher discount rate, more conservative revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple in their updated models. Analyst Commentary Bearish analysts are using the lower US$42 price target as a signal that they see less room for upside in CONMED at current levels, especially when they factor in higher discount rates and more cautious revenue assumptions.Narrative-Update • Jan 19
CNMD: Gastro Exit And Buybacks Will Support Future Margin Expansion
Analysts modestly adjusted their price target for CONMED, citing a slightly lower discount rate, unchanged fair value of $48.40, and minimal tweaks to long term growth and P/E assumptions that together fine tune their outlook rather than overhaul it. Analyst Commentary Bullish Takeaways Bullish analysts see the steady fair value estimate of $48.40, together with the slightly lower discount rate, as a sign that their view on CONMED’s risk profile and long term earnings power remains intact even after recent fine tuning.Narrative-Update • Jan 05
CNMD: Gastro Exit And Buybacks Will Support Margin Expansion Ahead
Analysts have trimmed their price target for CONMED to about US$48.40 from roughly US$54.00, pointing to slightly lower growth assumptions and a reduced future P/E multiple, partly balanced by a marginally higher profit margin outlook. What's in the News CONMED plans to exit its gastroenterology product lines, aiming to focus resources on core areas such as minimally invasive, robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair (Key Developments).Narrative-Update • Dec 20
CNMD: Focused Surgical Portfolio And Buybacks Will Support Stronger Future Returns
Analysts have lowered their price target on CONMED from 80.00 dollars to 55.00 dollars, citing slightly slower expected revenue growth and a higher discount rate that more than offset improved margin and valuation assumptions. What's in the News CONMED will exit its gastroenterology product lines to focus resources on core areas including minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair.Narrative-Update • Dec 06
CNMD: Margin Expansion And Buyback Program Will Drive Strong Future Returns
Analysts have nudged their price target on CONMED slightly higher to $54, citing modestly lower discount rate and revenue growth assumptions, offset by a slightly improved profit margin outlook and a marginally lower future P/E multiple that together support a stable valuation profile. Analyst Commentary Analyst views on CONMED remain balanced, with recent model tweaks reflecting a more nuanced outlook on growth, profitability, and valuation.Narrative-Update • Nov 22
CNMD: Margin Initiatives And Robust Buyback Will Drive Long-Term Shareholder Value
CONMED's analyst price target has been reduced from $56 to $54 per share, as analysts cite modest cuts to growth and profit outlooks, along with slightly higher discount rates following recent sector updates. Analyst Commentary Analysts have provided a range of perspectives on CONMED’s outlook based on recent developments in company performance and sector trends.Narrative-Update • Nov 07
CNMD: Improving Profit Margins And Robust Buyback Program Will Drive Shareholder Value
CONMED's analyst price target has been lowered from $61 to $56. This change reflects a more cautious stance as analysts point to expectations of slower revenue growth and a higher discount rate, despite improvements in underlying profit margins and future valuation multiples.Analyseartikel • Oct 06
These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Sep 12
CONMED (NYSE:CNMD) Has Announced A Dividend Of $0.20
CONMED Corporation ( NYSE:CNMD ) has announced that it will pay a dividend of $0.20 per share on the 3rd of October...Analyseartikel • Aug 08
CONMED's (NYSE:CNMD) Solid Profits Have Weak Fundamentals
CONMED Corporation ( NYSE:CNMD ) just reported some strong earnings, and the market reacted accordingly with a healthy...Analyseartikel • Jul 03
Are Investors Undervaluing CONMED Corporation (NYSE:CNMD) By 49%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, CONMED fair value estimate is US$107 Current share price of...Analyseartikel • May 24
CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
CONMED Corporation ( NYSE:CNMD ) will pay a dividend of $0.20 on the 3rd of July. This means the dividend yield will be...Analyseartikel • May 17
CONMED Corporation's (NYSE:CNMD) Shares Bounce 26% But Its Business Still Trails The Market
Those holding CONMED Corporation ( NYSE:CNMD ) shares would be relieved that the share price has rebounded 26% in the...Analyseartikel • Mar 31
Is CONMED (NYSE:CNMD) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 28
Repeated Disappointments On Growth And Margins Leaves Conmed Even Deeper In The Doghouse
Summary Conmed's ambitious revenue growth targets and ongoing operational issues have led to underperformance, with shares down 10% since my last update and ongoing concerns about growth, margins, and tariffs. Despite a decent Q4, Conmed's 2025 guidance was disappointing, with no margin expansion expected and a need to remediate supply and inventory issues. The threatened 25% tariff on goods imported from Mexico could severely affect earnings, adding to the company's existing operational and competitive challenges. While Conmed's valuation appears undemanding, significant risks and uncertainties suggest it may be prudent to wait for clearer signs of improvement before investing. Read the full article on Seeking AlphaAnalyseartikel • Feb 28
CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
CONMED Corporation ( NYSE:CNMD ) will pay a dividend of $0.20 on the 4th of April. This means the dividend yield will...Analyseartikel • Feb 08
CONMED Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that CONMED Corporation ( NYSE:CNMD ) filed its full-year result this time last week...Aktionärsrenditen
| CNMD | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 1.3% | 0.4% | -1.5% |
| 1Y | -8.5% | -12.6% | 17.8% |
Rendite im Vergleich zur Industrie: CNMD übertraf die Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -12.6 erzielte.
Rendite vs. Markt: CNMD hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 17.8 erzielte.
Preisvolatilität
| CNMD volatility | |
|---|---|
| CNMD Average Weekly Movement | 8.6% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: CNMD hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: CNMDDie wöchentliche Volatilität (9%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1970 | 3,900 | Pat Beyer | www.conmed.com |
CONMED Corporation, ein Medizintechnikunternehmen, entwickelt, produziert und vertreibt Geräte und Ausrüstungen für chirurgische Eingriffe. Das Unternehmen bietet Produkte für die orthopädische Chirurgie an, darunter BioBrace, TruShot mit Y-Knot All-In-One Soft Tissue Fixation System, Y-Knoten All-Suture Anchors und Agro Knotless Suture Anchors, die orthopädischen Chirurgen klinische Lösungen für die Augmentation und Reparatur von Weichteilverletzungen bieten, sowie unterstützende Produkte wie angetriebene Resektionsinstrumente, Flüssigkeitsmanagement- und Visualisierungssysteme und die dazugehörigen Einwegprodukte, die es Chirurgen ermöglichen, minimal-invasive sportmedizinische Operationen durchzuführen. Darüber hinaus bietet das Unternehmen unter dem Markennamen Hall surgical batteriebetriebene, autoklavierbare, große und kleine Knochenwerkzeugsysteme für den Einsatz in der Orthopädie, Arthroskopie, Mund-, Kiefer- und Gesichtschirurgie, Podologie, Wirbelsäulen- und Herz-Thorax-Chirurgie an.
CONMED Corporation's Grundlagenzusammenfassung
| CNMD grundlegende Statistiken | |
|---|---|
| Marktanteil | US$1.53b |
| Gewinn(TTM) | US$56.50m |
| Umsatz(TTM) | US$1.37b |
27.1x
Kurs-Gewinn-Verhältnis 1.1x
Kurs-Umsatz-VerhältnisIst CNMD zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| CNMD Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$1.37b |
| Kosten der Einnahmen | US$609.35m |
| Bruttogewinn | US$762.31m |
| Sonstige Ausgaben | US$705.81m |
| Gewinn | US$56.50m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 1.89 |
| Bruttomarge | 55.58% |
| Nettogewinnspanne | 4.12% |
| Schulden/Eigenkapital-Verhältnis | 80.0% |
Wie hat sich CNMD auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/23 08:46 |
| Aktienkurs zum Tagesende | 2026/08/21 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
CONMED Corporation wird von 16 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Travis Steed | Barclays |
| Vikramjeet Chopra | BMO Capital Markets Equity Research |
| Travis Steed | BofA Global Research |